This includes its use as an initial treatment for treatment-naïve patients with metastatic melanoma with or without BRAF V600 mutation where immunotherapy agents have been associated with durable long-term survival in patients with responding disease. The gene discussed is BRAF; the disease is metastatic melanoma.